WilmerHale Advises Embark Veterinary in $75M Series B Funding

WilmerHale Advises Embark Veterinary in $75M Series B Funding

Firm News

Related Solutions

Helping clients launch their businesses and transform their innovative ideas into successful companies.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

On July 26, 2021, Embark Veterinary, Inc., the top rated provider of dog DNA tests, announced that it secured $75 million in a Series B funding round led by SoftBank, with additional investors including F-Prime Capital, Slow Ventures, Freestyle Capital and Third Kind Venture Capital. Embark’s DNA-based analytics seeks to curb preventable diseases and increase the lifespan of dogs. The funding will be used to expand hiring and accelerate the development of Embark’s robust discovery engine.

The team representing Embark consisted of David A. Westenberg, Jon Jones, J.P. Mohler, and Cindy Sullivan.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel